CAMP4 Announces Pricing of Initial Public Offering

Company Overview - CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company focused on developing regulatory RNA-targeting therapeutics aimed at restoring healthy protein levels for various genetic diseases [5] - The company utilizes its proprietary RAP Platform™ to map regulatory RNAs and create therapeutic candidates targeting genes associated with over 1,200 disorders [5] Initial Public Offering (IPO) Details - CAMP4 announced the pricing of its IPO, offering 6,820,000 shares at $11.00 per share, with expected gross proceeds of approximately $75.0 million before expenses [1] - The common stock is set to begin trading on the Nasdaq Global Market under the ticker symbol "CAMP" on October 11, 2024, with the offering expected to close on October 15, 2024, subject to customary conditions [1] - Underwriters have a 30-day option to purchase an additional 1,023,000 shares at the IPO price [1] Underwriters - J.P. Morgan, Leerink Partners, Piper Sandler, and William Blair are acting as joint book-running managers for the offering [2]